These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6249870)

  • 1. Microneutalization of cytomegalovirus.
    Stalder H; Ehrensberger A
    J Infect Dis; 1980 Jul; 142(1):102-5. PubMed ID: 6249870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid microneutralization assay for cytomegalovirus.
    Gonczol E; Furlini G; Ianacone J; Plotkin SA
    J Virol Methods; 1986 Aug; 14(1):37-41. PubMed ID: 3021795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plaque reduction neutralization test for human cytomegalovirus based upon enhanced uptake of neutral red by virus-infected cells.
    Schmidt NJ; Dennis J; Lennette EH
    J Clin Microbiol; 1976 Jul; 4(1):61-6. PubMed ID: 182716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay.
    Lewis RB; Matzke DS; Albrecht TB; Pollard RB
    Rev Infect Dis; 1986; 8 Suppl 4():S434-8. PubMed ID: 3018894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cytomegalovirus polypeptides stimulate neutralizing antibody in vivo.
    Rasmussen L; Mullenax J; Nelson M; Merigan TC
    Virology; 1985 Aug; 145(1):186-90. PubMed ID: 2409670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of cytomegalovirus virions: the role of complement.
    Spiller OB; Hanna SM; Devine DV; Tufaro F
    J Infect Dis; 1997 Aug; 176(2):339-47. PubMed ID: 9237698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect immunofluorescence test for detection of IgM antibodies to cytomegalovirus.
    Hekker AC; Brand-Saathof B; Vis J; Meijers RC
    J Infect Dis; 1979 Oct; 140(4):596-600. PubMed ID: 229176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cytomegalovirus infection in an outpatient setting--laboratory markers and clinical aspects.
    Just-Nübling G; Korn S; Ludwig B; Stephan C; Doerr HW; Preiser W
    Infection; 2003 Oct; 31(5):318-23. PubMed ID: 14556056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental congenital infection with cytomegalovirus: a guinea pig model.
    Kumar ML; Nankervis GA
    J Infect Dis; 1978 Nov; 138(5):650-4. PubMed ID: 213503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies to cytomegaloviruses in normal simian and human sera.
    Minamishima Y; Graham BJ; Benyesh-Melnick M
    Infect Immun; 1971 Oct; 4(4):368-73. PubMed ID: 4343408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus.
    Andreoni M; Faircloth M; Vugler L; Britt WJ
    J Virol Methods; 1989 Feb; 23(2):157-67. PubMed ID: 2542350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of complement on cytomegalovirus neutralization by antibodies.
    Andersen HK
    Arch Gesamte Virusforsch; 1972; 36(1):133-40. PubMed ID: 4335019
    [No Abstract]   [Full Text] [Related]  

  • 13. Three-day assay for human cytomegalovirus applicable to serum neutralization tests.
    Waner JL; Budnick JE
    Appl Microbiol; 1973 Jan; 25(1):37-9. PubMed ID: 4346976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A vesicular stomatitis virus (cytomegalovirus) pseudotype and its use in neutralization tests.
    Vonka V; Závadová H; Poláková D
    Intervirology; 1979; 12(1):32-8. PubMed ID: 227814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional differences between antiviral activities of sulfonated and intact intravenous immunoglobulin preparations toward varicella-zoster virus and cytomegalovirus.
    Yajima M; Shiraki A; Daikoku T; Oyama Y; Yoshida Y; Shiraki K
    J Infect Chemother; 2015 Jun; 21(6):427-33. PubMed ID: 25824903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A microneutralization enzyme immunoassay for antibody to human cytomegalovirus.
    Tomiyama T; Sugano T; Tani S; Hosoda K; Matsumoto Y
    J Immunol Methods; 1993 Feb; 159(1-2):71-9. PubMed ID: 8383161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
    Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody responses to reinfecting strains of cytomegalovirus in transplant recipients.
    Chou SW
    J Infect Dis; 1989 Jul; 160(1):16-21. PubMed ID: 2543709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.
    Wang Z; La Rosa C; Maas R; Ly H; Brewer J; Mekhoubad S; Daftarian P; Longmate J; Britt WJ; Diamond DJ
    J Virol; 2004 Apr; 78(8):3965-76. PubMed ID: 15047812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation between acute primary and recurrent human cytomegalovirus infection in pregnancy, using a microneutralization assay.
    Eggers M; Metzger C; Enders G
    J Med Virol; 1998 Dec; 56(4):351-8. PubMed ID: 9829641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.